Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).

Hiroshige Yoshioka,Toyoaki Hida,Hiroshi Nokihara,Masahiro Morise,Young Hak Kim,Koichi Azuma,Takashi Seto,Yuichi Takiguchi,Makoto Nishio,Toru Kumagai,Katsuyuki Hotta,Satoshi Watanabe,Koichi Goto,Miyako Satouchi,Toshiyuki Kozuki,Kazuhiko Nakagawa,Tetsuya Mitsudomi,Nobuyuki Yamamoto,Takuya Yoshimoto,Tomohide Tamura

Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).

2021

9022Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-inhibitor naive ALK+ NSCLC demonstrated superior progression-free survival (PFS) in Japanese patients randomiz...

Keywords:

Cancer research
Lung cancer
ALK inhibitor
Alectinib
Medicine
non small cell
ALK-Positive
Crizotinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations